2022 was about execution. Now will Amgen’s growth strategy prove its worth?

Four of Amgen’s top drugs all saw record sales last quarter and strong annual growth, but the California-based biopharma company still has more than a couple remaining question marks to resolve moving into 2023 and beyond. In its Q4 earnings report yesterday, execs highlighted the success of its osteoporosis drug…

Click to view original post